Antares Pharma Company Profile (NASDAQ:ATRS)

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ATRS
  • CUSIP: 03664210
  • Web: www.antarespharma.com
Capitalization:
  • Market Cap: $467.66 million
  • Outstanding Shares: 156,407,000
Average Prices:
  • 50 Day Moving Avg: $3.04
  • 200 Day Moving Avg: $2.91
  • 52 Week Range: $1.37 - $3.37
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 299.00
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $53.1 million
  • Price / Sales: 8.81
  • Book Value: $0.26 per share
  • Price / Book: 11.50
Profitability:
  • EBIDTA: ($15,900,000.00)
  • Net Margins: -34.27%
  • Return on Equity: -41.37%
  • Return on Assets: -25.74%
Debt:
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 3.47%
  • Quick Ratio: 3.04%
Misc:
  • Average Volume: 1.39 million shs.
  • Beta: 0.46
  • Short Ratio: 6.8
 

Frequently Asked Questions for Antares Pharma (NASDAQ:ATRS)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) posted its earnings results on Tuesday, August, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The firm earned $13.42 million during the quarter, compared to analysts' expectations of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. View Antares Pharma's Earnings History.

Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2017?

4 brokers have issued 12 month price targets for Antares Pharma's shares. Their forecasts range from $4.00 to $5.00. On average, they expect Antares Pharma's stock price to reach $4.58 in the next year. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:

  • Leonard S. Jacob M.D., Ph.D., Independent Chairman of the Board
  • Robert F. Apple CPA, President, Chief Executive Officer, Director
  • Fred M. Powell CPA, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer
  • Peter J. Graham, Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer
  • Thomas J. Garrity, Independent Director
  • Jacques Gonella Ph.D., Independent Director
  • Anton G. Gueth, Independent Director
  • Robert P. Roche Jr., Independent Director
  • Marvin S. Samson, Independent Director

Who owns Antares Pharma stock?

Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.97%), Broadfin Capital LLC (3.07%), Rubric Capital Management LP (2.04%), State Street Corp (1.30%), JW Asset Management LLC (1.07%) and Northern Trust Corp (1.06%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, James E Flynn, Leonard S Jacob, Peter J Graham, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Who sold Antares Pharma stock? Who is selling Antares Pharma stock?

Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Kingdon Capital Management L.L.C., Goldman Sachs Group Inc., Veritable L.P. and Oppenheimer & Co. Inc.. Company insiders that have sold Antares Pharma stock in the last year include Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Who bought Antares Pharma stock? Who is buying Antares Pharma stock?

Antares Pharma's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Rubric Capital Management LP, Vanguard Group Inc., TIAA CREF Investment Management LLC, JW Asset Management LLC, Bank of New York Mellon Corp and Wells Fargo & Company MN. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham and Robert F Apple. View Insider Buying and Selling for Antares Pharma.

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of Antares Pharma stock can currently be purchased for approximately $2.99.


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.25)
Consensus Price Target: $4.58 (53.01% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/10/2017HC WainwrightReiterated RatingBuy$5.00LowView Rating Details
9/8/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
6/23/2017Chardan CapitalInitiated CoverageBuy$5.00HighView Rating Details
4/20/2017Raymond James Financial, Inc.Initiated CoverageStrong-Buy$4.30LowView Rating Details
5/10/2016Jefferies Group LLCReiterated RatingBuy$3.00N/AView Rating Details
9/25/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$4.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Antares Pharma (NASDAQ:ATRS)
Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)
Earnings History by Quarter for Antares Pharma (NASDAQ ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.03)($0.02)$12.99 million$13.42 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
2017 EPS Consensus Estimate: ($0.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20172($0.03)($0.03)($0.03)
Q3 20172($0.04)($0.03)($0.04)
Q4 20172($0.05)($0.02)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Antares Pharma (NASDAQ:ATRS)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 36.77%
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)
Insider Trades by Quarter for Antares Pharma (NASDAQ:ATRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Fred M PowellInsiderBuy130,000$2.79$362,700.00View SEC Filing  
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Antares Pharma (NASDAQ:ATRS)
Latest Headlines for Antares Pharma (NASDAQ:ATRS)
Source:
DateHeadline
finance.yahoo.com logoAntares Pharma to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 5:00 PM
finance.yahoo.com logoIs There Now An Opportunity In Antares Pharma Inc (ATRS)?
finance.yahoo.com - September 19 at 9:10 PM
americanbankingnews.com logo Brokerages Expect Antares Pharma, Inc. (ATRS) Will Post Quarterly Sales of $13.62 Million
www.americanbankingnews.com - September 14 at 1:08 AM
seekingalpha.com logoAntares Pharma (ATRS) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 9:27 PM
finance.yahoo.com logoAntares: Positive Phase III Trials May Support the Case for Approval of Xyosted
finance.yahoo.com - September 12 at 4:24 PM
finance.yahoo.com logoETFs with exposure to Antares Pharma, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:15 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - September 10 at 6:24 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Receives "Buy" Rating from Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 3:06 PM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 2:54 AM
finance.yahoo.com logoAntares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 4:35 PM
finance.yahoo.com logoAntares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 4:35 PM
globenewswire.com logoAntares Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:56 PM
finance.yahoo.com logoAntares Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 5:47 PM
bizjournals.com logoMedical Supplies Stock Performance Review -- Integra LifeSciences, Antares Pharma, Becton, Dickinson and Co., and Waters
www.bizjournals.com - August 31 at 4:02 PM
americanbankingnews.com logo$13.79 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - August 27 at 7:48 AM
finance.yahoo.com logoAntares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : August 25, 2017
finance.yahoo.com - August 25 at 5:49 PM
americanbankingnews.com logo Analysts Anticipate Antares Pharma, Inc. (ATRS) Will Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - August 25 at 12:58 PM
finance.yahoo.com logoAntares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : August 21, 2017
finance.yahoo.com - August 22 at 9:57 PM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 15 at 2:56 AM
americanbankingnews.com logoZacks Investment Research Weighs in on Antares Pharma, Inc.'s FY2017 Earnings (NASDAQ:ATRS)
www.americanbankingnews.com - August 11 at 11:18 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Antares Pharma, Inc. Increased by Analyst (NASDAQ:ATRS)
www.americanbankingnews.com - August 11 at 9:48 AM
finance.yahoo.com logoAntares Pharma, Inc. breached its 50 day moving average in a Bearish Manner : ATRS-US : August 10, 2017
finance.yahoo.com - August 10 at 3:45 PM
americanbankingnews.com logoJefferies Group Analysts Raise Earnings Estimates for Antares Pharma, Inc. (NASDAQ:ATRS)
www.americanbankingnews.com - August 10 at 1:46 PM
americanbankingnews.com logoZacks Investment Research Analysts Increase Earnings Estimates for Antares Pharma, Inc. (NASDAQ:ATRS)
www.americanbankingnews.com - August 10 at 1:40 PM
finance.yahoo.com logoEdited Transcript of ATRS earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 2:20 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Expected to Announce Quarterly Sales of $12.99 Million
www.americanbankingnews.com - August 9 at 7:46 AM
nasdaq.com logoAntares Pharma Reports Second Quarter 2017 Operating And Financial Results - Nasdaq
www.nasdaq.com - August 8 at 3:58 PM
finance.yahoo.com logoAntares Pharma Reports Second Quarter 2017 Operating And Financial Results
finance.yahoo.com - August 8 at 3:57 PM
finance.yahoo.com logoAntares Pharma reports 2Q loss
finance.yahoo.com - August 8 at 3:57 PM
globenewswire.com logoAntares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call - GlobeNewswire (press release)
globenewswire.com - August 1 at 5:04 PM
feeds.benzinga.com logoAntares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
feeds.benzinga.com - August 1 at 7:23 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Sees Large Decline in Short Interest
www.americanbankingnews.com - July 28 at 1:46 AM
prnewswire.com logoToday's Research Report Coverage on Medical Supplies Stocks -- Antares Pharma, Integra LifeSciences, Becton ... - PR Newswire (press release)
www.prnewswire.com - July 25 at 4:07 PM
americanbankingnews.com logo Brokerages Expect Antares Pharma, Inc. (NASDAQ:ATRS) Will Announce Quarterly Sales of $12.99 Million
www.americanbankingnews.com - July 19 at 10:56 AM
americanbankingnews.com logo-$0.03 EPS Expected for Antares Pharma, Inc. (NASDAQ:ATRS) This Quarter
www.americanbankingnews.com - July 18 at 12:22 AM
americanbankingnews.com logoShort Interest in Antares Pharma, Inc. (NASDAQ:ATRS) Increases By 179.3%
www.americanbankingnews.com - July 14 at 7:04 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Cut to Hold at Vetr Inc.
www.americanbankingnews.com - July 13 at 12:50 AM
americanbankingnews.com logoAntares Pharma, Inc. (NASDAQ:ATRS) Upgraded at Vetr Inc.
www.americanbankingnews.com - July 9 at 4:10 PM
finance.yahoo.com logoETFs with exposure to Antares Pharma, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 7:11 AM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Downgraded by Vetr Inc.
www.americanbankingnews.com - June 26 at 11:58 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Juno Therapeutics and Antares Pharma
finance.yahoo.com - June 26 at 4:15 PM
finance.yahoo.com logoETFs with exposure to Antares Pharma, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 4:15 PM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 10:53 AM
americanbankingnews.com logoZacks: Brokerages Expect Antares Pharma, Inc. (ATRS) Will Post Quarterly Sales of $13.32 Million
www.americanbankingnews.com - June 23 at 1:42 PM
americanbankingnews.com logoAntares Pharma, Inc. (ATRS) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - June 23 at 9:06 AM
americanbankingnews.com logoAntares Pharma's (ATRS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - June 23 at 8:22 AM
americanbankingnews.com logoAntares Pharma Inc (ATRS) Expected to Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - June 21 at 8:32 PM
seekingalpha.com logoAntares Looks Strong Ahead Of Multiple FDA Decisions
seekingalpha.com - June 20 at 4:19 PM
seekingalpha.com logoAntares Pharma: Focus On Xyosted - Seeking Alpha
seekingalpha.com - June 16 at 4:26 PM

Social

Chart

Antares Pharma (ATRS) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff